Introduction
============

Methotrexate (MTX) is an effective immunosuppressant that is widely used as a standard therapy for rheumatoid arthritis (RA).^[@B1]^ Among its various adverse effects, lymphoma was reported for the first time in 1991 in a patient with RA who was taking weekly low-dose MTX.^[@B2]^ Since that time, lymphoproliferative disorder (LPD) as a result of immunosuppression caused by MTX (MTX-associated LPD; MTX-LPD) has been attracting attention.^[@B3]^ MTX-LPDs are categorized as "other iatrogenic immunodeficiency-associated LPDs" in the World Health Organization's classification.^[@B4]^ Characteristically, MTX-LPD can regress spontaneously after stopping MTX.^[@B3],[@B5]^ This suggests that the tumor cells proliferate because of MTX-induced immunosuppression. Additionally, MTX-LPD may be associated with Epstein-Barr virus (EBV); 30%--50% of patients with MTX-LPD are reportedly EBV^+^.^[@B3]^ Extranodal lesions are found in 40%--50% of MTX-LPD patients,^[@B3]^ commonly at the gastrointestinal tract, skin, liver, and lungs.^[@B3],[@B5],[@B6]^ However, MTX-LPD in the central nervous system (CNS) is extremely rare, with few reported cases.^[@B7]--[@B15]^ Here, we describe a rare case of primary CNS MTX-LPD in a patient with RA, and review the literature.

Case Report
===========

Clinical history and presentation
---------------------------------

A 68-year-old woman with a 2-day history of motor aphasia and right hemiparesis was referred to our hospital because of CNS lesions. She had been receiving MTX (8 mg/week) for her RA for more than 10 years.

Laboratory data showed a normal white blood cell count (8000/µL). Her serum soluble interleukin (IL)-2 receptor was slightly elevated (542 U/mL; normal: 145--519 U/mL). Her levels of serum lactate dehydrogenase level (189 IU/L; normal: 106--211 IU/L), C-reactive protein (0.2 mg/dL; normal: \< 0.6 mg/dL) and serum β2-microglobulin (1.5 mg/L; normal: 0.9--1.9 mg/L) were normal. Serological tests for human immunodeficiency virus, human T-cell lymphotropic virus type 1, and cytomegalovirus were negative. EBV antibody showed a pattern indicative of previous infection (EB-VCA-IgG, 640 titer; EBV-VCA-IgM, negative; anti-EBNA, 40 titer). The cerebrospinal fluid protein content was slightly elevated at 46 mg/dL, but the cell count was normal.

Head magnetic resonance imaging (MRI) showed multiple lesions scattered throughout both hemispheres with heterogeneous contrast enhancement on gadolinium contrast-enhanced T1-weighted images and peritumoral edema on fluid attenuation inversion recovery images ([Fig. 1A](#F1){ref-type="fig"} and [1B](#F1){ref-type="fig"}). Whole-body computed tomography (CT) showed no apparent lymphadenopathies or other lesions suggestive of malignancy. The imaging-based differential diagnoses were metastasis, malignant lymphoma, or glioma.

![(**A**) Preoperative gadolinium-enhanced T1-weighted head magnetic resonance images shows multiple lesions with heterogeneous contrast enhancement. (**B**) Fluid attenuation inversion recovery images show surrounding high-intensity area.](nmccrj-7-121-g001){#F1}

Immunosuppression caused by MTX was also suspected and MTX was discontinued, based on a working diagnosis of MTX-LPD. However, on Day 4 after admission, the patient's right hemiparesis worsened; a head CT showed expanded peritumoral edema. Therefore, we performed an open biopsy of the right temporal lesion for a definitive diagnosis on Day 9 after admission and initiated steroid therapy.

Pathological and molecular findings
-----------------------------------

Microscopic histopathologic examination of the tumor specimen showed proliferation of atypical lymphoid cells (hematoxylin and eosin; [Fig. 2A](#F2){ref-type="fig"}). These atypical lymphoid cells were CD20^+^ ([Fig. 2B](#F2){ref-type="fig"}). *In situ* hybridization of an Epstein-Barr virus-encoded small RNA (EBER) was positive ([Figs. 2C](#F2){ref-type="fig"} and [2D](#F2){ref-type="fig"}). A definitive diagnosis of diffuse large B-cell lymphoma (DLBCL) was established.

![(**A**) Hematoxylin and eosin staining shows proliferation of medium-sized atypical lymphoid cells (× 400). (**B**) Atypical lymphoid cells were positive for CD20 (× 400). (**C**) *In situ* hybridization of an EBER was positive (× 400). (**D**) Atypical lymphoid cells were doubly positive for double staining for CD20 and EBER (× 400). EBER: Epstein-Barr virus-encoded small RNA.](nmccrj-7-121-g002){#F2}

To detect *MYD88* L265 and *CD79B* Y196 mutations, which are frequent mutations in primary CNS lymphoma (PCNSL), genomic DNA was extracted from formalin-fixed and paraffin-embedded specimens using a QIAamp DNA FFPE Tissue Kit (Qiagen, Hilden, Germany) and amplified by polymerase chain reaction. We used the following primer sequences: *MYD88* L265: forward primer, 5\'-GGGATGGCTGTTGTTAACCCT-3\' and reverse primer, 5\'-GGTGTAGTCGCAGACAGTGAT-3\'.^[@B16]^ *CD79B* Y196: forward primer, 5\'-TCTTGCAGAATGCACCTCAC-3\' and reverse primer, 5\'-GCAGCGTCACTATGTCCTCA-3\'.^[@B17]^ The polymerase chain reaction products were then sequenced on a 3130xl genetic analyzer (Applied Biosystems, Foster City, CA, USA) with a Big Dye Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems), in accordance with the manufacturer's instructions. Sanger sequencing confirmed that both *MYD88* L265 and *CD79B* Y196 mutations were absent ([Figs. 3A](#F3){ref-type="fig"} and [3B](#F3){ref-type="fig"}).

![(**A**) *MYD88* L265 mutation was absent. (**B**) *CD79B* Y196 mutation was absent.](nmccrj-7-121-g003){#F3}

Clinical outcome
----------------

The patient's postoperative course was uneventful and her neurological symptoms gradually improved. Three weeks after withdrawing MTX, a head MRI showed decreased high-intensity areas on fluid attenuation inversion recovery images and multiple contrast-enhanced lesions on gadolinium contrast-enhanced T1-weighted images. She was discharged without neurological symptoms, and her RA has remained stable with low-dose corticosteroids. A follow-up head MRI at 8 months after surgery showed no evidence of recurrence ([Figs. 4A](#F4){ref-type="fig"} and [4B](#F4){ref-type="fig"}).

![(**A**) Follow-up gadolinium contrast-enhanced T1-weighted magnetic resonance images and (**B**) fluid attenuation inversion recovery images at 8 months after surgery show no evidence of recurrence.](nmccrj-7-121-g004){#F4}

Discussion
==========

Here, we report a rare case of primary CNS MTX-LPD in a patient with RA, in whom DLBCL was definitively diagnosed by an open biopsy. The patient's disease course was typical for EBV^+^ MTX-LPD. Her LPD spontaneously regressed after MTX cessation.

Characteristics of primary CNS MTX-LPD
--------------------------------------

In a literature search, we found nine cases of primary CNS MTX-LPD, which are summarized with the present case in [Table 1](#T1){ref-type="table"}.^[@B7]--[@B15]^ The primary disease was RA in all 10 patients. The affected primary CNS MTX-LPD sites were the cerebrum (8/10), medulla (1/10), and dura (1/10). Of the eight cases of cerebral MTX-LPD, seven (including our case) presented as multiple lesions; only one case presented as a solitary lesion.[@B7]^,^[@B8]^,^[@B10]^,^[@B11]^,[@B13]--[@B15]^ One case with medullary LPD presented with a solitary mass,^[@B9]^ and a case with hypertrophy of the dura mater presented as intravascular large B-cell lymphoma (IVLBCL).^[@B12]^

###### Reported cases of primary central nervous system methotrexate-associated lymphoproliferative disorder

       Study                    Age/ sex   MTX mg/week (yr)       Other immune suppressors   Neurological symptoms                         LPD site/properties                 Biopsy site           Histopathology                                                                                EBER   Regression after MTX withdrawal   Additional LPD treatment                          Outcome                                                   Follow-up duration
  ---- ------------------------ ---------- ---------------------- -------------------------- --------------------------------------------- ----------------------------------- --------------------- --------------------------------------------------------------------------------------------- ------ --------------------------------- ------------------------------------------------- --------------------------------------------------------- --------------------
  1    Kleinschmidt 2008.^7)^   78/F       Standard dose (\>10)   NA                         NA                                            Cerebrum, multiple lesions          Cerebrum              P/L LPD                                                                                       Yes    Yes                               No                                                Died 3 mo later; multi-organ failure attributable to RA   3 mo
  2    Fukushima 2013.^8)^      64/F       6 (4)                  No                         Headache, dementia                            Cerebrum, multiple lesions          Cerebrum              PTCL-NOS                                                                                      Yes    Yes (transient)                   High-dose MTX with leucovorin rescue              Good                                                      1 yr
  3    Migita 2013.^9)^         53/F       8 (1)                  Bucillamine, PRD           Nausea, vomiting, vertigo, double vision      Medulla, single lesion              Medulla               DLBCL                                                                                         Yes    Yes                               Resection of mass                                 Good                                                      8 yr
  4    Liu 2015.^10)^           58/M       10 (2)                 No                         Depression, nausea, vomiting                  Cerebrum, multiple lesions          Cerebrum              DLBCL                                                                                         No     NA                                Radiotherapy                                      Good                                                      1 yr
  5    Shimada 2015.^11)^       60s/F      14 (7)                 ETN, ADL, PRD              Convulsion                                    Cerebrum, multiple lesions          Cervical lymph node   NC (dispersed Hodgkin-like large cells with CD20^+^ lymphocytes)                              Yes    Yes                               No                                                Good                                                      \>1 yr
  6    Kikuchi 2016.^12)^       50/F       8 (3)                  ETN, ADL                   No                                            Hypertrophy of frontal dura mater   Skin, subcutaneous    IVLBCL                                                                                        No     Partial improvement               R-CHOP + intrathecal CT (PRD+ MTX + cytarabine)   Good                                                      2 yr
  7    Matsuda 2018.^13)^       76/F       NA (2)                 No                         Staggering gait                               Cerebrum, multiple lesions          Cerebrum              NC (perivascular proliferation of CD20^+^ lymphoid cells)                                     Yes    Yes                               NA                                                NA                                                        NA
  8    Uchida 2018.^14)^        52/F       8 (4)                  ETN                        Dementia, hemiparesis                         Cerebrum, multiple lesions          Cerebrum              DLBCL                                                                                         No     No                                Rituxan + high-dose MTX + cytarabine, RT          Died 17 mo after onset                                    17 mo
  9    Miyaza 2019.^15)^        68/F       16 (5)                 No                         Hemiparesis, dysgraphia, speech disturbance   Cerebrum, single lesion             Cerebrum              NC (dense proliferation of CD20^+^ lymphocytes with atypical nuclei in perivascular lesion)   Yes    Yes                               No                                                Good                                                      \>3 yrs
  10   Present case             68/F       8 (\>10)               No                         Motor aphasia, hemiparesis                    Cerebrum, multiple lesions          Cerebrum              DLBCL                                                                                         Yes    Yes                               No                                                Good                                                      8 mo

All patients' primary disease was RA.

ADL: adalimumab, CT: chemotherapy, DLBCL: diffuse large B-cell lymphoma, EBER: Epstein-Barr virus-encoded small RNA, ETN: Etanercept, F: female, HL LPD: Hodgkin's lymphoma--like lymphoproliferative disorder, IVLBCL: intravascular large B-cell lymphoma, LPD: lymphoproliferative disorder, M: Male, mo: months, MTX: Methotrexate, NA: not available, NC: non-classifiable, P/L LPD: polymorphic/lymphoplasmacytic lymphoproliferative disorder, PRD: Prednisolone, PTCL-NOS: peripheral T-cell lymphoma, not otherwise specified, RA: rheumatic arthritis, R-CHOP: rituximab + cyclophosphamide + vincristine + adriamycin + prednisolone, RT: radiotherapy, yr: years.

The age range at diagnosis of primary CNS MTX-LPD was 50--78 years, which is similar to that reported for all MTX-LPDs, including other sites (all-site; median: 67 years, range: 34--87 years).^[@B3]^ Although most primary CNS MTX-LPD occurred in women, as reported for all-site MTX-LPDs, the ratio of women to men for primary CNS MTX-LPD is higher than for all-site MTX-LPDs (9:1 vs 2:1).^[@B3]^

The median dose of MTX treatment in primary CNS MTX-LPD is 8 mg/week (range: 6--16 mg/week); and the median duration of MTX treatment until primary CNS MTX-LPD diagnosis is 4 years (range, 1 year to \>10 years). These values are similar to those for all-site MTX-LPD cases (8.4 \[range, 5.9--10.0\] mg/week, 4--6 years).^[@B3],[@B18],[@B19]^ A higher MTX dose is associated with LPD development in RA patients. Other immune suppressors, such as adalimumab, bucillamine, etanercept, and prednisolone, were used in four primary CNS MTX-LPD cases.[@B9]^,[@B11],[@B12],[@B14]^

Neurological symptoms depend on the location of primary CNS MTX-LPD ([Table 1](#T1){ref-type="table"}). Patients with cerebral lesions presented with headache, dementia, dysgraphia, convulsion, speech disturbance, motor aphasia, hemiparesis, depression, nausea, and vomiting.[@B7]^,^[@B8]^,^[@B10]^,^[@B11]^,[@B13]--[@B15]^ A patient with a medullary lesion presented with nausea, vomiting, vertigo, and double vision.^[@B9]^ A patient with hypertrophy of the dura mater presented as IVLBCL had no neurological symptoms.^[@B12]^

Biopsy for exact diagnosis of CNS MTX-LPD
-----------------------------------------

Biopsy is an important method to determine diagnosis and treatment strategy in these patients. In the present case, we performed an open biopsy of the right temporal lesion. Biopsy sites of primary CNS MTX-LPD cases including the present case were the cerebrum (7/10), medulla (1/10), skin (1/10), and cervical lymph node (1/8; [Table 1](#T1){ref-type="table"}) In two cases (Cases 5 and 6), cervical lymph node or skin were biopsied rather than the CNS lesion^[@B11],[@B12]^; the authors concluded that the CNS lesions and biopsy sites were from the same origins, because after stopping MTX, these lesions regressed.

Histopathology of CNS MTX-LPD
-----------------------------

Several histologic patterns were reported in CNS MTX-LPD, with DLBCL as the most common (4/10); polymorphic/lymphoplasmacytic lymphoproliferative disorder (P/L LPD; 1/10), peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS; 1/10), Hodgkin's lymphoma--like lymphoproliferative disorder (HL LPD; 1/10), and non-classifiable patterns (3/10) were also reported. These results are similar to those for all-site MTX-LPDs, in which DLBCL was the most common histologic patterns (35--50%), followed by Hodgkin lymphoma (10--30%).^[@B4],[@B18],[@B20]^

Genomic alterations in CNS MTX-LPD and PCNSL
--------------------------------------------

In our patient, both *MYD88* L265 and *CD79B* Y196 mutations were absent. MTX-LPD is presumed to have a distinct molecular profile compared with PCNSL; however, to date, genomic alterations in MTX-LPD, including CNS MTX-LPD, remain unconfirmed because of the rarity of the disease. In PCNSL, B-cell receptor/nuclear factor-κB (NF-κB) signaling is the core pathway.^[@B21]--[@B23]^ Additionally, *MYD88* L265 and *CD79B* Y196 mutations may play a key role in up-regulating NF-κB.^[@B21]--[@B23]^ *MYD88* encodes a signaling adaptor protein that induces activation of NF-κB and the JAK/STAT3 pathway after stimulating Toll-like receptors, interferon-β production, and IL-1/IL-18 receptors.^[@B24]^ The *CD79B* gene encodes a B-cell antigen receptor (BCR) subunit that is essential for BCR signaling, resulting in NF-κB activation.^[@B24]^ An *MYD88* L265 mutation was reported to occur in 76%--85% of patients with PCNSL, and a *CD79B* Y196 mutation has been reported in 83% of patients.^[@B22],[@B23]^ The prevalence of *MYD88* and *CD79B* mutations in PCNSL was considerably higher than that reported for systemic DLBCL.^[@B22],[@B23]^

EBER expression and regression after MTX withdrawal in CNS MTX-LPD
------------------------------------------------------------------

EBV is an oncogenic virus associated with several malignant diseases, including Burkitt's lymphoma and non-Hodgkin lymphoma. Although EBV^+^ MTX-LPD cases often spontaneously regress after withdrawal of MTX, this is less common in EBV^−^ cases.^[@B3]^ This suggests that MTX has possible effects on the regulation of EBV gene expression, which reactivates EBV. In EBV^+^ MTX-LPD cases, MTX activates EBV promoters and stimulates viral replication.^[@B25]^ Then, excessive proliferation and survival of EBV-infected lymphoid cells are induced, leading to the development of LPD.^[@B25]^ Withdrawal of MTX abrogates signals for proliferation and/or survival, leading to spontaneous regression without additional chemotherapy.^[@B25]^ The low expression of the antiapoptotic protein, Bcl-2 protein, and the low hypermethylation of apoptosis-related genes in EBV^+^ MTX-LPD cases may explain the rapid regression of LPD after withdrawing MTX.^[@B25]^

We found that 7/10 (70%) of the primary CNS MTX-LPD cases to be EBER+, which is a little higher than reported for all-site MTX-LPDs (30--50%).^[@B3],[@B4]^

Withdrawal of MTX is the initial treatment for MTX-LPD. Regression of LPD after stopping MTX was reported in eight (89%) of the nine cases of primary CNS MTX-LPD including the present case, and the remaining case had no information about this point ([Table 1](#T1){ref-type="table"}). This rate of the spontaneous regression after MTX withdrawal only is higher than reported for all-site MTX-LPDs (25--60%).[@B3]^,[@B4],[@B18],[@B26]^ All seven EBER^+^ cases including the present case showed regression after stopping MTX, whereas the two EBER^−^ cases (Cases 6 and 8) showed partial or no regression after stopping MTX.^[@B12],[@B14]^ These results are consistent with results reported for all-site MTX-LPDs; patients with spontaneous regression after MTX withdrawal had a significantly higher rate of EBV positivity (85% vs 50%).^[@B18]^

In some CNS MTX-LPD cases, including the present case, steroid therapy combined with MTX withdrawal was used to alleviate the symptoms.^[@B11],[@B15]^ Steroid therapy for PCNSL works rapidly to cause tumor regression and decrease peritumoral edema^[@B27]^; therefore, it is the treatment of choice for short-term palliation. However, because steroid therapy obscures the histological diagnosis of PCNSL, steroid therapy before biopsy should be avoided as much as possible.^[@B28]^

Regrowth following regression after MTX withdrawal and additional treatments for CNS MTX-LPD
--------------------------------------------------------------------------------------------

In one EBER^+^ case (Case 2), the lesions regrew after initially regressing when MTX was withdrawn and additional chemotherapy was performed.^[@B8]^ The 2 EBER^−^ patients (Cases 6 and 8) showed only partial or no regression after stopping MTX, and received additional chemotherapy.^[@B12],[@B14]^ In these three patients, MTX was included in additional chemotherapy regimens.^[@B8],[@B12],[@B14]^ However, according to the 2016 update of the Japan College of Rheumatology recommendations for the use of MTX in patients with RA, LPD within the most recent 5 years is included in the contraindications for MTX.^[@B29]^ Therefore, using MTX as additional LPD treatment should be avoided. In Case 3, the mass was completely resected when the biopsy was performed, and the authors suggested that perfect surgical resection contributed to non-recurrence of LPD in their case.^[@B9]^ According to the reports of all-site MTX-LPDs, subsequent regrowth or relapse occurred in 18%--45% of patients whose MTX-LPD spontaneously regressed.[@B3]^,[@B4],[@B18],[@B26]^ After spontaneous MTX-LPD regression, patients should be followed up and rigorously monitored, even when they show no sign of recurrence. If remission does not occur after stopping MTX or relapse occurs after spontaneous regression, chemotherapy or radiotherapy should be considered. However, there are no standardized chemotherapy regimens across institutions; various regimens are used to treat LPD in patients with RA. R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) was the most frequently reported regimen, but various other regimens have been reported.^[@B29]^ The treatment regimen should be selected in consultation with hematologists according to histopathology and the anatomical stages of LPD.^[@B29]^

Treatment of RA after MTX withdrawal
====================================

According to the 2016 update of the Japan College of Rheumatology recommendations for the use of MTX in patients with RA, the treatment of RA after LPD regression should not include immunosuppressive drugs, as much as possible, and MTX rechallenge and the use of tumor necrosis factor inhibitors should be avoided.^[@B19]^ However, withdrawing MTX in RA patients with LPD may result in enhanced RA activity and requires treatment intensification. Similar to the treatment of RA in general, corticosteroids, conventional synthetic disease-modifying antirheumatic drugs (DMARDs), and biological DMARDs have been used for such cases.^[@B25]^ In patients with low to moderate RA activity, the use of low-dose corticosteroids is a reasonable option, but treating RA with high disease activity is a difficult challenge, clinically.^[@B25]^

In patients with CNS MTX-LPD, some reports have described RA treatment after MTX withdrawal. In Case 3, prednisolone plus salazosulfapyridine was used after CNS MTX-LPD resection.^[@B9]^ However, the patient's RA disease activity was high; therefore, the authors introduced abatacept, and the patient's RA improved remarkably. In Case 9 and the present case, RA activity remained stable with low-dose corticosteroids.^[@B14]^ Follow-up of RA activity after MTX withdrawal and adjusting the treatment according to the patient's RA activity are necessary.

Conclusions
===========

In conclusion, we report a rare case of primary CNS MTX-LPD in a patient with RA. Use of MTX has increased because MTX is widely used as a standard therapy for RA. Although CNS MTX-LPD is extremely rare, it should be considered in the differential diagnosis when a patient who receives MTX develops CNS lesions. An early diagnosis by biopsy and MTX discontinuation as soon as possible are required. Follow-up is necessary, even for patients who show no sign of recurrence.
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